Vivacelle Bio Receives $5.3M Award for Treatment of Septic Shock, the Cause of 70% of COVID Deaths
Vivacelle's VBI-S is likely to be effective in elevating blood pressure to survivable levels and improving oxygenation at early and even late stages of septic shock when current therapy, consisting of fluids and vasopressor medications, have failed.